Drug-Drug Interaction Study in Healthy Subjects

Open-Label, Randomized, Multiple-Dose, Drug-Drug Interaction Study to Assess the Pharmacokinetics and Safety of BMS-790052 and BMS-650032 Co-administered in Healthy Subjects

The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone

Pharmacokinetics and Safety in Healthy Subjects

Inclusion Criteria:

• Healthy male and female subjects aged 18 to 49 years
• Females who are not of childbearing potential, pregnant or breastfeeding
• Subject Body Mass Index (BMI) of 18 to 32 kg/m²

Exclusion Criteria:

• Women of child bearing potential
• Male subjects who have sex with women who are unwilling to agree to practice male barrier contraception during study participation and for a least 12 weeks following dosing
• Any significant acute or chronic medical illness
• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
• Prior exposure to BMS-650032 or BMS-790052
• Positive for HIV or HCV